Stock XENE XENON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
42.49 USD +4.53% Intraday chart for Xenon Pharmaceuticals Inc. +7.57% -7.75%
04-19 Xenon Pharmaceuticals Inc. Announces Board Resignations CI
03-11 Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Business Summary

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Number of employees: 255

Managers

Managers TitleAgeSince
Ian Mortimer CEO
 Chief Executive Officer 48 20/10/13
Simon Pimstone FOU
 Founder 56 04/11/96
Sherry Aulin DFI
 Director of Finance/CFO 40 31/12/10
Christopher Kenney CTO
 Chief Tech/Sci/R&D Officer - 22/08/21
Sheila M. Grant CTO
 Chief Tech/Sci/R&D Officer - 31/07/20
Jodi Regts IRO
 Public Communications Contact - 30/11/15
Chris von Seggern PRN
 Corporate Officer/Principal - 16/08/20
Andrea DiFabio LAW
 General Counsel 55 06/11/22
James Empfield PRN
 Corporate Officer/Principal - 31/01/16
Robin Sherrington PRN
 Corporate Officer/Principal 63 28/02/01

Members of the board

Members of the board TitleAgeSince
Clarence Machado BRD
 Director/Board Member 60 04/11/20
Mohammad Azab BRD
 Director/Board Member 68 30/09/03
Justin Gover BRD
 Director/Board Member 53 07/08/23
Gary Patou BRD
 Director/Board Member 65 31/12/03
Simon Pimstone FOU
 Founder 56 04/11/96
Steven Gannon BRD
 Director/Board Member 62 20/05/15
Ian Mortimer CEO
 Chief Executive Officer 48 20/10/13
Dawn Svoronos BRD
 Director/Board Member 70 26/09/16
Elizabeth Garofalo BRD
 Director/Board Member 66 02/06/21
Gillian Cannon BRD
 Director/Board Member 60 07/08/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 75,463,489 74,078,341 ( 98.16 %) 0 98.16 %

Shareholders

NameEquities%Valuation
Avoro Capital Advisor LLC
7.512 %
5,666,666 7.512 % 244 M $
Fidelity Management & Research Co. LLC
7.498 %
5,655,922 7.498 % 243 M $
Driehaus Capital Management LLC
5.760 %
4,345,180 5.760 % 187 M $
Wellington Management Co. LLP
5.518 %
4,162,654 5.518 % 179 M $
POLAR CAPITAL HOLDINGS PLC
4.065 %
3,066,628 4.065 % 132 M $
Capital Research & Management Co. (World Investors)
3.555 %
2,681,537 3.555 % 115 M $
Capital Research & Management Co. (International Investors)
3.255 %
2,455,683 3.255 % 106 M $
Commodore Capital LP
2.874 %
2,167,793 2.874 % 93 M $
Paradigm BioCapital Advisors LP
2.820 %
2,127,400 2.820 % 92 M $
Pictet Asset Management Holding SA
2.705 %
2,040,400 2.705 % 88 M $

Company contact information

Xenon Pharmaceuticals, Inc.

3650 Gilmore Way Suite 200

V5G 4W8, Burnaby

+604 484 3300

http://www.xenon-pharma.com
address Xenon Pharmaceuticals Inc.(XENE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
42.49 USD
Average target price
57.44 USD
Spread / Average Target
+35.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XENON PHARMACEUTICALS INC. Stock Xenon Pharmaceuticals Inc.
-7.75% 3.07B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 96.09B
ARGENX SE Stock argenx SE
+2.13% 22.28B
BIONTECH SE Stock BioNTech SE
-14.77% 21.4B
GENMAB A/S Stock Genmab A/S
-8.79% 18.14B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.09B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 13.83B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 11.97B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XENE Stock
  4. Company Xenon Pharmaceuticals Inc.